Joint Diseases
1
Pipeline Programs
2
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
J&
OD
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Johnson & Johnsonoxycodone CR
Johnson & Johnsonoxycodone CR
Ortho DevelopmentRoutine Total Hip Arthroplasty
Clinical Trials (3)
Total enrollment: 940 patients across 3 trials
A Safety and Efficacy Study of JNS024 Extended Release (ER) in Japanese and Korean Patients With Chronic Malignant Tumor-Related Cancer Pain
Start: Aug 2010Est. completion: Aug 2012343 patients
Phase 3Completed
A Study to Compare the Frequency of Constipation Symptoms With Tapentadol Immediate Release (IR) Treatment Versus Oxycodone IR Treatment in Patients With End-stage Joint Disease
Start: Oct 2008Est. completion: Jul 2009597 patients
Phase 3Completed
Survivorship and Patient Outcomes of Primary Total Hip Arthroplasty With the Ovation Hip System
Start: Jun 2019Est. completion: Jun 2024
N/AUnknown
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
2 companies competing in this space